drugset / Trial / NCT02228239

Study to Assess the Effects of Esketamine on Safety of On-road Driving in Healthy Participants

NCT02228239

Phase 1 Completed 26 enrolled Janssen Research & Development, LLC
RandomizedCrossoverDouble-blindPrevention

Summary

The purpose of this study is to evaluate the effect of esketamine compared to placebo on driving performance as assessed by the mean difference of standard deviation of lateral position (SDLP) from an on-road driving test in healthy participants.

Timeline

Start
2014-09
Primary completion
2014-12
Completion
2014-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Esketamine Other / unclassified 84 mg Intranasal
Subject Mirtazapine Other / unclassified 30 mg Oral

Indications

No indication recorded.